颈动脉多普勒超声对慢性肾病患者动脉粥样硬化程度及血流动力学的评估价值

doi:10.3969/j.issn.1004-583X.2021.11.010

摘要/Abstract

摘要：

目的分析颈动脉多普勒超声对慢性肾病患者动脉粥样硬化程度及血流动力学的评估价值。方法前瞻性将2020年6月至2021年1月沈阳医学院附属第二医院肾内科收治的慢性肾病血液透析者纳入血液透析组(n=40),接受腹膜透析者纳入腹膜透析组(n=40),另择同期健康体检者纳入健康对照组(n=40)。比较各组颈总动脉内中膜厚度,左侧颈总动脉、左侧颈内动脉、右侧颈总动脉、右侧颈内动脉峰值血流速度、舒张末血流速度。结果腹膜透析组、血液透析组颈总动脉内中膜厚度高于健康对照组(P<0.05)。健康对照组左侧颈总动脉、左侧颈内动脉、右侧颈总动脉、右侧颈内动脉峰值血流速度、舒张末血流速度低于血液透析组、腹膜透析组(P<0.05),血液透析组左侧颈总动脉、左侧颈内动脉、右侧颈总动脉、右侧颈内动脉峰值血流速度、舒张末血流速度低于腹膜透析组(P<0.05)。结论慢性肾病患者透析类型与动脉粥样硬化密切相关,颈动脉多普勒超声指标可量化检测患者血流动力学指标,对防治慢性肾病患者发生动脉粥样硬化具有积极意义。

关键词: 肾疾病, 超声检查, 多普勒, 肾透析, 动脉粥样硬化, 血流动力学

Abstract:

Objective To analyze the evaluation of carotid doppler ultrasonography(CDU) in degree of atherosclerosis and hemodynamics of atherosclerosis in patients with chronic kidney disease(CKD).Methods Totally 80 CKD patients admitted to Department of Nephrology, the Second Affiliated Hospital of Shenyang Medical College from June 2020 to January 2021 were prospectively enrolled. The patients were classified into hemodialysis group (n=40), peritoneal dialysis group (n=40), 40 healthy subjects who underwent regular physical examinations during the same period randomly in control group. The key observation was carotid intima-media thickness(CIMT), left common carotid artery(LCCA), left internal carotid artery(LICA), right common carotid artery(RCCA), blood flow velocity(BFV) in right internal carotid artery(RICA), end diastolic velocity(EVD) between groups. Results CIMT in peritoneal dialysis group and hemodialysis group obviously increased in comparing with control group (P<0.05). LCCA, LICA, RCCA, BFV in RICA and EVD decreased notably in control group when compared with peritoneal dialysis group and hemodialysis group (P<0.05), which were significantly lower in hemodialysis group than in peritoneal dialysis group (P<0.05). Conclusion The dialysis type of CKD patients is closely related to atherosclerosis degree. CDU can quantitatively detect the hemodynamic indices, which has positive significance in preventing and treating atherosclerosis in CKD patients.

Key words: kidney diseases, ultrasonography, doppler, renal dialysis, hemodynamics

中图分类号:

R692.9

王超, 万多, 李卅立, 王曦. 颈动脉多普勒超声对慢性肾病患者动脉粥样硬化程度及血流动力学的评估价值[J]. 临床荟萃, 2021, 36(11): 1009-1012.

Wang Chao, Wan Duo, Li Sali, Wang Xi. Evaluation of carotid Doppler ultrasonography in degree and hemodynamics of atherosclerosis of chronic kidney disease[J]. Clinical Focus, 2021, 36(11): 1009-1012.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2021.11.010

https://huicui.hebmu.edu.cn/CN/Y2021/V36/I11/1009

图/表 3

参考文献 14

[1]	Zhao B, Chen A, Wang H, et al. The relationship between sclerostin and carotid artery atherosclerosis in patients with stage 3-5 chronic kidney disease[J]. Int Urol Nephrol, 2020, 52(7):1329-1336. doi: 10.1007/s11255-020-02495-x pmid: 32458213
[2]	Kaya B, Seyrek N, Paydas S, et al. Serum fibroblast growth factor 23 levels do not correlate with carotid intima-media thickness in patients with chronic kidney disease[J]. Saudi J Kidney Dis Transpl, 2019, 30(5):1010-1021. doi: 10.4103/1319-2442.270255 URL
[3]	Tomita I, Kume S, Sugahara S, et al. SGLT2 inhibition mediates protection from diabetic kidney disease by promoting ketone body-induced mtorc1 inhibition[J]. Cell Metab, 2020, 32(3):404-419. doi: S1550-4131(20)30358-2 pmid: 32726607
[4]	杨爽, 刘锋, 李淼, 等. 慢性肾脏病患者微炎症致动脉粥样硬化的机制研究进展[J]. 中国实验诊断学, 2020, 24(3):530-532.
[5]	孙井来, 韦成相, 韩文淮, 等. 数字减影CT血管成像与彩色多普勒超声对颈动脉粥样硬化斑块检出率及斑块性质、狭窄程度判定的效果比较[J]. 国际放射医学核医学杂志, 2018, 42(6):513-517.
[6]	唐清华, 罗开琴. 彩色多普勒超声在心肌梗死合并高血压病患者颈动脉粥样硬化狭窄程度及斑块分布检测中的应用[J]. 解放军医药杂志, 2019, 31(9):44-47.
[7]	Kaya B, Paydas S, Aikimbaev K, et al. Prevalence of cardiac arrhythmia and risk factors in chronic kidney disease patients[J]. Saudi J Kidney Dis Transpl, 2018, 29(3):567-577. doi: 10.4103/1319-2442.235178 URL
[8]	Zhao B, Chen A, Wang H, et al. The relationship between sclerostin and carotid artery atherosclerosis in patients with stage 3-5 chronic kidney disease[J]. Int Urol Nephrol, 2020, 52(7):1329-1336. doi: 10.1007/s11255-020-02495-x pmid: 32458213
[9]	陈倩倩, 李秀云, 郑金珏, 等. 超声评价青老年颈动脉粥样硬化斑块临床价值[J]. 医学研究杂志, 2020, 49(1):118-121, 127.
[10]	Fakhry M, Sidhu MS, Bangalore S, et al. Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease[J]. Rev Cardiovasc Med, 2020, 21(2):157-162. doi: 10.31083/j.rcm.2020.02.99 URL
[11]	杨文艳, 王建爽, 王艳辉. 维持性血液透析病人颈动脉粥样硬化超声评估及影响因素分析[J]. 中西医结合心脑血管病杂志, 2018, 16(12):1790-1792.
[12]	Rangaswami J, Bhalla V, de Boer IH, et al. Cardiorenal protection with the newer antidiabetic agents in patients with diabetes and chronic kidney disease: A scientific statement from the American Heart Association[J]. Circulation, 2020, 142(17):e265-e286.
[13]	Ito K, Maeda T, Tada K, et al. The role of cigarette smoking on new-onset of chronic kidney disease in a Japanese population without prior chronic kidney disease: Iki epidemiological study of atherosclerosis and chronic kidney disease (ISSA-CKD)[J]. Clin Exp Nephrol, 2020, 24(10):919-926. doi: 10.1007/s10157-020-01914-8 URL
[14]	罗川. 颈动脉多普勒超声对慢性肾病患者动脉粥样硬化程度及血流动力学的诊断价值[J]. 中国医学物理学杂志, 2019, 36(4):479-482.

组别	例数	左侧颈总动脉	右侧颈总动脉
血液透析组	40	0.98±0.12^*	1.01±0.17^*
腹膜透析组	40	1.05±0.18^*	1.04±0.19^*
健康对照组	40	0.81±0.14	0.82±0.16
F值		12.486	18.852
P值		<0.01	<0.01

组别	例数	左侧颈总动脉	右侧颈总动脉
血液透析组	40	0.98±0.12^*	1.01±0.17^*
腹膜透析组	40	1.05±0.18^*	1.04±0.19^*
健康对照组	40	0.81±0.14	0.82±0.16
F值		12.486	18.852
P值		<0.01	<0.01

组别	例数	左侧颈总动脉	左侧颈内动脉	右侧颈总动脉	右侧颈内动脉
血液透析组	40	69.29±5.65^*#	67.11±5.52^*#	66.67±0.62^*#	67.76±4.52^*#
腹膜透析组	40	73.68±6.33^*	74.88±5.18^*	70.58±7.12^*	72.15±6.41^*
健康对照组	40	42.73±6.27	61.17±7.93	43.61±4.14	60.58±7.01
F值		302.344	47.196	202.454	36.995
P值		<0.01	<0.01	<0.01	<0.01

组别	例数	左侧颈总动脉	左侧颈内动脉	右侧颈总动脉	右侧颈内动脉
血液透析组	40	69.29±5.65^*#	67.11±5.52^*#	66.67±0.62^*#	67.76±4.52^*#
腹膜透析组	40	73.68±6.33^*	74.88±5.18^*	70.58±7.12^*	72.15±6.41^*
健康对照组	40	42.73±6.27	61.17±7.93	43.61±4.14	60.58±7.01
F值		302.344	47.196	202.454	36.995
P值		<0.01	<0.01	<0.01	<0.01

组别	例数	左侧颈总动脉	左侧颈内动脉	右侧颈总动脉	右侧颈内动脉
血液透析组	40	19.37±2.26^*#	30.58±3.34^*#	18.31±2.18^*#	30.32±2.76^*#
腹膜透析组	40	24.84±2.18^*	34.24±3.39^*	23.79±2.45^*	35.61±2.72^*
健康对照组	40	14.07±2.14	23.58±4.36	12.12±2.30	21.13±3.37
F值		241.009	84.514	254.954	244.274
P值		<0.01	<0.01	<0.01	<0.01